文献速递细菌感染、耐药与抗菌药物

咽部淋病治疗的疗效:随机对照试验的系统评价与荟萃分析

Treatment efficacy for pharyngeal Neisseria gonorrhoeae: a systematic review and meta-analysis of randomized controlled trials.
PubMed 文献 · J Antimicrob Chemother · 2020-01-01

该系统评价纳入2000年至2019年9项RCT共452例15岁及以上咽部淋病患者,评估19种方案的微生物学治愈率。总体疗效98.1%(95%CI 93.8%-100%),含头孢曲松或阿奇霉素2g的方案(单用或联合)疗效最佳,新兴药物为88.8%。

要点

  • 含头孢曲松或阿奇霉素2g的方案对咽部淋病疗效最高。
  • 单药与联合治疗疗效相似,总体治愈率98.1%。
  • 新兴药物疗效估计为88.8%,需进一步研究。

核心结论

  • 含头孢曲松或阿奇霉素2g的方案单用或联合治疗对咽部淋病最有效。

研究设计与样本

  • 系统评价与荟萃分析,检索2000年1月1日至2019年9月17日数据库,纳入9项RCT共452例15岁及以上咽部淋病患者,评估19种方案。

主要发现

  • 咽部淋病总体治疗疗效为98.1%(95%CI 93.8%-100%;I2=57.3%;P<0.01)。
  • 单药治疗疗效97.1%(95%CI 90.8%-100.0%;I2=15.6%;P=0.29),联合治疗98.0%(95%CI 91.4%-100%;I2=79.1%;P<0.01)。
  • 含阿奇霉素2g或头孢曲松的方案疗效相似。
  • 新兴药物汇总疗效估计为88.8%(95%CI 76.9%-97.5%;I2=11.2%;P=0.34)。

关键数值与推荐

  • 推荐含头孢曲松或阿奇霉素2g的方案(单用或联合)用于咽部淋病治疗。
  • 新兴药物疗效较低(88.8%),需更多咽部特异性RCT验证。

临床怎么用

  • 临床治疗咽部淋病可优先选择含头孢曲松或阿奇霉素2g的方案。
  • 对新兴药物应谨慎评估,等待更多证据。

局限性

  • 各试验样本量小是主要局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Rising gonorrhoea rates require highly effective treatments to reduce transmission and prevent development of antimicrobial resistance. Currently the most effective treatments for pharyngeal gonorrhoea remain unclear. This review aimed to estimate treatment efficacy for pharyngeal gonorrhoea. METHODS: Online bibliographic databases were searched for the period 1 January 2000 to 17 September 2019 for treatments of gonorrhoea. All randomized controlled trials (RCTs) with data on pharyngeal gonorrhoea among participants aged 15 years or above, published in English, were included. Meta-analyses (random effects) were used to estimate the treatment efficacy, defined as microbiological cure, among currently recommended monotherapies and dual therapies, previously recommended but no longer used regimens and emerging drugs under evaluation. Side effects were also summarized. The study protocol was registered on PROSPERO (CRD42020149278). RESULTS: There were nine studies that included 452 participants studying 19 treatment regimens. The overall treatment efficacy for pharyngeal gonorrhoea was 98.1% (95% CI: 93.8%-100%; I2 = 57.3%; P < 0.01). Efficacy was similar for single (97.1%; 95% CI: 90.8%-100.0%; I2 = 15.6%; P = 0.29) and dual therapies (98.0%; 95% CI: 91.4%-100%; I2 = 79.1%; P < 0.01). Regimens containing azithromycin 2 g or ceftriaxone were similarly efficacious. The summary efficacy estimate for emerging drugs was 88.8% (95% CI: 76.9%-97.5%; I2 = 11.2%; P = 0.34). Small sample sizes in each trial was a major limitation. CONCLUSIONS: Regimens containing ceftriaxone or azithromycin 2 g, alone or as part of dual therapies are the most efficacious for pharyngeal gonorrhoea. Further pharyngeal-specific RCTs with adequate sample sizes are needed.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Kong FYS, Hatzis CL, Lau A, et al. Treatment efficacy for pharyngeal Neisseria gonorrhoeae: a systematic review and meta-analysis of randomized controlled trials. J Antimicrob Chemother. 2020. PMID: 32747940. doi:10.1093/jac/dkaa300

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。